Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988371 | 1.00 | MEN1 (0.34) | MEN1KMT2ALTA4HESR1ESR2 | |
| SCHEMBL2786926 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL28992248 | 0.77 | MEN1 (0.36) | MEN1KMT2ALTA4HESR1ESR2 | |
| SCHEMBL27256342 | 0.77 | LPAR3 (0.42) | MEN1KMT2AESR1ESR2CHRM2 | |
| SCHEMBL14346017 | 0.76 | MEN1 (0.32) | MEN1KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL14346014 | 0.76 | MEN1 (0.32) | MEN1KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL14346049 | 0.76 | MEN1 (0.32) | MEN1KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL7159583 | 0.76 | TSHR (0.34) | MEN1KMT2ACHRM2CHRM1CHRM3 | |
| SCHEMBL5176752 | 0.76 | CHRM2 (0.37) | LTA4HCHRM2CHRM1CHRM3CHRNB2 | |
| SCHEMBL28992249 | 0.73 | CHRM2 (0.34) | MEN1KMT2ALTA4HESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172895-A1 | METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING | LACHESIS BIOSCIENCES LIMITED (AU) | 2023-06-08 | — | — | US | claimed |
| US-20230172895-A1 | METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING | LACHESIS BIOSCIENCES LIMITED (AU) | 2023-06-08 | — | — | US | disclosed |
| US-9132135-B2 | Method of treating organophosphorous poisoning | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-09-15 | — | — | US | disclosed |
| US-20090023706-A1 | Method of Treating Organophosphorous Poisoning | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172895-A1 | METHODS OF TREATING OR PREVENTING ORGANOPHOSPHORUS POISONING | ACHE, BCHE, CHRM3 | MEN1 600/4885KMT2A 1020/4885LTA4H 486/4885 |
| US-20090023706-A1 | Method of Treating Organophosphorous Poisoning | ACHE, BCHE, GALC | MEN1 2226/4885KMT2A 1581/4885LTA4H 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.